Epidemiological studies have found that low 25-hydroxyvitamin D levels may be associated with coronary risk factors and adverse cardiovascular outcomes. Additionally, vitamin D deficiency causes an increase in parathyroid hormone, which increases insulin resistance and is associated with diabetes, hypertension, inflammation, and increased cardiovascular risk. In this review, we analyze the association between vitamin D supplementation and the reduction in cardiovascular disease. The role of vitamin D deficiency in cardiovascular morbidity and mortality is still controversial, and larger scale, randomized placebo-controlled trials are underway to address this issue. These results from these studies will likely not be available for another 3-5 years. At this stage, we propose recommendations for preventing vitamin D deficiency and conclude that there is a benefit to vitamin D supplementation.

© 2013 Baishideng. All rights reserved.

Key words: Cardiovascular disease; Morbidity; Mortality; Review; Vitamin D

Core tip: We performed an extensive review to determine whether vitamin D supplementation reduces cardiovascular risk. Only double-blind, placebo- and randomized-controlled trials were included. The role of vitamin D deficiency in cardiovascular morbidity and mortality is still controversial, and larger scale, randomized placebo-controlled trials are underway to address this issue. These results from these studies will likely not be available for another 3-5 years. At this stage, we propose recommendations for preventing vitamin D deficiency and conclude that there is a benefit to vitamin D supplementation.

Ku YC, Liu ME, Ku CS, Liu TY, Lin SL. Relationship between vitamin D deficiency and cardiovascular disease. World J Cardiol 2013; 5(9): 337-346 Available from: URL: http://www.wjgnet.com/1949-8462/full/v5/i9/337.htm DOI: http://dx.doi.org/10.4330/wjc.v5.i9.337

INTRODUCTION

Vitamin D is likely one of the oldest hormones, having existed for at least 750 million years[1]. Studies have demonstrated that low levels of vitamin D represent a problem of global dimensions[2-12]. A recent Workshop Consensus for Vitamin D Nutritional Guidelines estimated that approximately 50% and 60% of the elderly in...
North America and the rest of the world, respectively, do not have satisfactory vitamin D levels\[14\]. The situation is similar in younger subjects. Reasons for this widespread deficiency remain unclear but are likely related to factors such as urbanization, demographic shifts, decreased outdoor activity, air pollution and global dimming, as well as decreases in the cutaneous production of vitamin D with age. Epidemiological pooled analysis of prospective observational studies of diverse populations demonstrates that hypovitaminosis D is associated with a modest risk of cardiovascular events\[15-20\]. The amount of vitamin D obtained from dietary sources is generally viewed as too low in many regions of the world to have an effect on the vitamin D status at the population level\[10\]. This review introduces the general concept of vitamin D, defines vitamin D deficiency, evaluates the relationship between vitamin D deficiency and cardiovascular disease, proposes a recommendation for preventing vitamin D deficiency and offers conclusions.

**NATURE OF VITAMIN D**

There are 2 major forms of vitamin D, vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). Vitamin D2 is found in plants and can be consumed in fortified foods or as a supplement. Vitamin D3 is obtained from either dietary sources or through the conversion of 7-dehydrocholesterol in the skin upon exposure to ultraviolet B (UVB) radiation\[10,21\]. Vitamin D3 from the skin is bound to the vitamin D-binding protein, whereas vitamin D2 and vitamin D3 from diet are bound to vitamin D-binding protein and lipoproteins. Both forms are hydroxylated in the liver to form 25-hydroxyvitamin D [25(OH)D; D represents D2 or D3]. However, 25(OH)D is inactive and requires hydroxylation in the kidney to form 1,25-dihydroxyvitamin D [1,25(OH)2D, calcitriol]. Calcitriol [1,25(OH)2D] maintains calcium in the blood and has an array of effects on the body’s organs. Calcitriol acts in an endocrine manner to regulate calcium metabolism by enhancing intestinal calcium absorption and mobilizing calcium from the skeleton\[10,19,22,23\]. Although 1,25(OH)2D is considered to be the active form of vitamin D, its levels in the serum do not correlate with overall vitamin D status, whereas the 25(OH)D levels is a more clinically relevant marker\[28\]. Vitamin D activity is measured in μg of 25(OH)D (1 μg = 40 International Units, IU). The minimum desirable serum level of 25(OH)D has been suggested to be 20-30 ng/mL according to the consensus conference\[14\].

Dietary sources of vitamin D are limited to fatty fish (wild or farm salmon, mackerel, tuna fish, sardines, and cod liver oil) and products fortified with vitamin D, which include dairy products, cereals, margarine, flour, and orange juice\[24,25\].

**DEFINITION OF VITAMIN D DEFICIENCY**

Several measures have been used to define vitamin D deficiency, insufficiency, and adequacy. A 25(OH)D of < 20 ng/mL is associated with suppressible levels of parathyroid hormone when challenged with pharmacologic dosages of vitamin D\[26\]. Parathyroid hormone levels begin to reach their nadir when the 25(OH)D levels are > 30 ng/mL\[27,28\]. Intestinal calcium absorption in adults is maximized when 25(OH)D is > 30 ng/mL\[29\]. Thus, many experts define vitamin D deficiency, insufficiency, and sufficiency as levels of < 20, 21 to 29, and > 30 ng/mL, respectively. To achieve these levels, a minimum of 1000 IU of vitamin D2 or vitamin D3 is needed daily when sun exposure is either unavailable or inadequate for producing vitamin D3, such as during the winter or when a sunscreen is used\[30\].

In the United States, Europe, India, Asia, Middle East, New Zealand, and Australia, vitamin D deficiency is common in pregnant women, newborns, young and adolescent children, and the elderly\[32,37\]. Serum vitamin D levels are lower in European young adults than in North American young adults during winter\[37\]. Vitamin D deficiency is especially common in people of color or who avoid sunlight\[38\].

**RELATIONSHIP BETWEEN VITAMIN D DEFICIENCY AND CARDIOVASCULAR DISEASE**

Numerous studies have found high rates of CV diseases among patients with lower levels of vitamin D. More recently, low levels of 25(OH)D have been linked to the presence of cardiovascular disease, hypertension, and the metabolic syndrome\[16-20\]. It is still unclear whether supplementation with vitamin D is beneficial to cardiovascular health. To this end, we have performed an extensive survey of published studies. Only double-blinded and randomized controlled trials (RCT) were included. The databases searched include MEDLINE, EMBASE, and PUBMED from January 1966 to May 2013. We selected search terms that capture generic and specific words relevant to the exposure and outcome on the basis of Medical Subject Heading terms and text words from a priori identified key articles. The terms selected for vitamin D were the following: “vitamin D intake, vitamin D supplement, calcidiol, calcitriol, cholecalciferol, and ergocalciferol”. The terms selected for cardiovascular disease (CVD) were the following: “cardiovascular disease, ischemic heart disease, coronary artery disease, cardiovascular mortality, myocardial infarction, and stroke”. We restricted the search to articles published in English and studies of humans that double-blinded and RCT. We applied the same search strategy to each database. Because of the limitations in assessing cause-effect relationships, we excluded ecological, cross-sectional, and retrospective case-control studies. By screening abstracts, we also excluded case reports, studies of vitamin D combination treatment (e.g., combined vitamin D + calcium supplementation), and studies that did not assess the use of...
vitamin D supplementations. We retrieved articles that passed the abstract screening test for a full-text review, and we further excluded review articles, editorials, or letters to editors as well as studies lacking a comparison between participants who received vitamin D supplementation and non-recipients.

After the abstract screening and full-text review, we selected 19 eligible articles. Ten articles favored beneficial cardiovascular effects after supplementation with vitamin D (Table 1)\(^{[43-52]}\). A trial in the United States randomly assigned 283 African American subjects into a 4-arm, double-blind trial of placebo, 1000, 2000, or 4000 IU of oral cholecalciferol per day. At baseline and 3 mo, the systolic and diastolic pressure and 25(OH)D were measured. This study found that although cholecalciferol supplementation did not affect the diastolic pressure (\(P = 0.37\)), the difference in systolic pressure between baseline and 3 mo was +1.17 mmHg for those receiving placebo, -0.66 mmHg for 1000 U/d, -3.4 mmHg for 2000 U/d, and -4.0 mmHg for 4000 U/d of cholecalciferol (\(-1.4 \) mmHg for each additional 1000 U/d of cholecalciferol; \(P = 0.04\)). For each 1-ng/mL increase in the plasma 25(OH)D, there was a significant 0.2-mmHg reduction in the systolic pressure (\(P = 0.02\))\(^{[43]}\). Larsen et al\(^{[46]}\) investigated the effect of 3000 IU vitamin D per day for 20 wk in a randomized, placebo-controlled, double-blind study in 130 hypertensive patients residing in Denmark. Vitamin D supplementation reduced the systolic pressure significantly. In a post-hoc subgroup analysis of 92 subjects with baseline p-25(OH)D levels < 32 ng/mL, significant decreases in the 24-h systolic and diastolic BP were observed in response to cholecalciferol supplementation\(^{[45]}\). Similar reports relevant to “vitamin D supplementation produces beneficial cardiovascular effects” are summarized in Table 1.

In contrast, the remaining nine articles did not find a cardioprotective effect of vitamin D supplementation (Table 2)\(^{[43-44]}\). In Ireland, 202 healthy adults (20-40 years old) and 192 healthy elders (≥ 64 years old) were recruited and received vitamin D supplementation at a dosage of 0, 200, 400, or 600 IU for 22 wk. Serum 25(OH)D, intact parathyroid hormone, systolic and diastolic blood pressure, fasting lipids, glucose and insulin, high-sensitivity CRP, matrix metalloproteinase-9, and its inhibitor (tissue inhibitor metalloproteinase-1) were measured at baseline and 22 wk later, which was the endpoint. This study revealed that there were no significant effects of supplementation on the CVD risk biomarkers in either age group\(^{[46]}\). Wood et al\(^{[60]}\) conducted a parallel-group, double-blind, placebo- and randomized-controlled trial in 305 healthy postmenopausal women to test whether daily doses of vitamin D3 at 400 or 1000 IU/d for 1 year affected the conventional markers of cardiovascular disease risk. The serum lipid profile (total, high-density lipoprotein, and low-density lipoprotein cholesterol; triglycerides; and apolipoproteins A-1 and B100), insulin resistance (homeostatic model assessment), inflammatory biomarkers (high-sensitivity C-reactive protein, IL-6, and soluble intracellular adhesion molecule-1), and blood pressure were studied. They found that dietary vitamin D supplementation is unlikely to reduce CVD risk factors, such as serum lipid profile, insulin resistance, inflammatory biomarkers, and blood pressure\(^{[60]}\). Additional reports that did not find a cardioprotective effect of vitamin D supplementation are summarized in Table 2\(^{[43-59,60]}\).

**MECHANISMS FOR THE CARDIOVASCULAR EFFECTS OF VITAMIN D DEFICIENCY**

The results of recent nationwide investigations showed an association between low 25(OH)D levels and important cardiovascular risk factors\(^{[46,62]}\) and further supported the findings of preclinical and clinical investigations that demonstrated positive effects of vitamin D and its...
Calcitriol treatment reduces levels of blood pressure, plasma rennin activity and angiotensin II. Calcitriol is a negative endocrine regulator of the rennin-angiotensin-aldosterone system (RAAS). The RAAS plays a central role in the regulation of blood pressure, electrolytes, and volume hemostasis. Calcitriol treatment reduces blood pressure, plasma rennin activity and angiotensin II levels.

**Table 1** Double-blind, placebo- and randomized-controlled trials that favor supplement with vitamin D may have a beneficial cardiovascular effects

| Ref.          | Country      | Participants                  | Intervention                          | Duration of follow-up | Results                                      |
|---------------|--------------|-------------------------------|---------------------------------------|-----------------------|----------------------------------------------|
| Forman et al[64] | United States | 283 African-American subjects | Oral vitamin D3 (cholecalciferol, 1000, 2000, or 4000 IU), or placebo per day for 3 mo | 6 mo                  | Reduction in systolic pressure.             |
| Harris et al[65] | United States | 45 African-American adults    | 60000 IU monthly oral vitamin D(3) or placebo for 16 wk | 16 wk            | Effective at improving vascular endothelial function |
| Larsen et al[66] | Denmark      | 112 Hypertensive patients     | 75 μg (3000 IU) cholecalciferol per day or placebo for 20 wk | 20 wk             | Significant decreases in systolic blood pressure |
| Lind et al[67] | Sweden       | 65 subjects with impaired glucose tolerance | Alphacalcidol (0.75 microgram daily) or placebo over 12 wk | 12 wk             | Significant reduction of blood pressure     |
| Lind et al[68] | Sweden       | 65 Hypertensive patients with primary hyperparathyroidism | Alphacalcidol, (1 microgram daily) or placebo over 6 mo | 6 mo              | Significant reduction of blood pressure     |
| Longenecker et al[69] | United States | 45 HIV-infected individuals with vitamin D deficiency | Vitamin D3 4000 IU daily or placebo for 12 wk | 12 wk             | Modestly improved cholesterol              |
| Salehpour et al[70] | Iran        | 77 healthy premenopausal overweight and obese women | Vitamin D (25 μg/d as cholecalciferol) or the placebo group for 12 wk | 12 wk             | Significantly improvement of HDL-cholesterol, apoA-I concentrations and LDL-cholesterol: apoB-100 ratio. |
| Shedeed[49]    | Egypt        | 80 infants with CHF           | Vitamin D(3) oral drops or placebo oral drops for 12 wk | 12 wk             | Significant improvement of HF score, LV end-diastolic diameter, LV end-systolic diameter, LV ejection fraction%, and myocardial performance index. |
| Witham et al[71] | United Kingdom | 58 stroke patients             | 100000 units of a single oral dose of vitamin D2 or placebo | 16 wk             | Short-term improvement in endothelial function (Flow mediated dilatation was significantly higher in the intervention group at 8 wk) |
| Zittermann et al[72] | Germany     | 200 healthy overweight subjects in a weight-reduction program | Vitamin D (83 microg/d) or placebo for 12 mo | 12 mo             | Significant improvement of cardiovascular disease risk markers |

LV: Left-ventricular; CHF: Congestive heart failure; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; IU: International units.

Analogues on fibrinolysis, blood lipids, thrombogenicity, endothelial regeneration, and smooth muscle cell growth[88-90]. Together, these findings strongly suggest that 25(OH)D has beneficial effects, some involving the cardiovascular system, that are independent of calcium metabolism. Several mechanisms might be responsible for the protective effect of calcitriol on atherosclerotic lesions and vascular calcification (Figure 1). First, vascular smooth cells express vitamin D receptors. Calcitriol inhibits proliferation of these cells with an acute influx of calcium into the cells[89,90]. Second, a lack of calcitriol results in an increase in the serum parathyroid hormone (PTH) levels. Excess PTH levels may at least in part promote cardiovascular disease by increased the cardiac contractility and myocardial calcification[91]. Third, experimental studies have shown that calcitriol suppresses the release of the inflammatory cytokines such as tissue necrosis factor-α (TNF-α), IL-6, and IL-10. There is now increasing evidence that inflammatory processes play an important role in the development of a vascular insult[92,93]. Fourth, calcitriol is a negative endocrine regulator of the rennin-angiotensin-aldosterone system (RAAS). The RAAS plays a central role in the regulation of blood pressure, electrolytes, and volume hemostasis. Calcitriol treatment reduces blood pressure, plasma rennin activity and angiotensin II levels[89]. Fifth, vascular smooth muscle cell proliferation and migration, as well as the osteogenic processes may contribute to the vascular calcification, which may eventually cause the thrombogenesis[94]. Sixth, vitamin D plays a role in the insulin sensitivity, which has a role in diabetes and in metabolic syndrome[95,96]. Essential hypertension is related to several disturbances in the systemic and cellular calcium metabolism. Extracellular ionized or ultrafiltrable calcium levels are decreased while intracellular cytosolic calcium concentrations are increased. Dietary calcium intake is often lower and renal calcium loss is higher in hypertensive than in normotensive subjects. Epidemiologic studies have demonstrated an inverse association between serum 25(OH)D levels and diastolic blood pressure[97]. Moreover, Afro-Americans have a significantly higher prevalence of diastolic hypertension and have lower 25(OH)D levels compared with white Americans[88,92,93]. In clinical trials, the daily administration of 5 μg of vitamin D showed no effects on blood pressure in normotensive subjects. However, some studies have demonstrated a blood pressure lowering effect with 0.75 or 1.0 μg vitamin D/d in hypertensive patients[98]. Short-term supplementation with 20 μg of vitamin D/d significantly reduced diastolic blood pressure. A reduction in the diastolic and systolic blood pressure was observed in mildly hypertensive patients after 6 wk of UV-B exposure[88,94].
of the enhanced intracellular calcium levels seems to be an important measure for reducing blood pressure, which can explain the therapeutic effects of calcium-channel blockers in hypertensive patients\(^{[95,96]}\). Low adenylate cyclase activity can result in a decreased calcium re-uptake into the sarcoplasmic reticulum and can contribute to an accumulation of intracellular free calcium and to an increase in vascular reactivity and blood pressure\(^{[97]}\). Activity of the intracellular adenylate cyclase is calcitriol-dependent and improvement of the activity of this enzyme may thus reduce free cellular calcium concentrations.

Hyperlipidemia, diabetic mellitus, and an increase in blood coagulation factors, blood viscosity, and leukocyte counts are important risk factors for the development of arteriosclerosis. There is now increasing evidence that arteriosclerosis is a low-grade systemic inflammatory disease. An increase in serum C-reactive protein levels is an important indicator of inflammatory reactions and also of the risk of developing arteriosclerosis\(^{[98]}\). The synthesis of C-reactive protein is regulated by IL-6 and IL-10 as well as TNF-\(\alpha\)\(^{[7,99]}\). Animal studies have demonstrated that IL-6 and IL-10 accelerate arteriosclerosis\(^{[100]}\). Calcitriol can suppress the secretion of TNF-\(\alpha\) and IL-6 in vitro in a dose-dependent manner\(^{[101]}\). A recent study identified an inverse association between TNF-\(\alpha\) and 25(OH)D levels in human subjects\(^{[102]}\).

### PREVENTION OF VITAMIN D INSUFFICIENCY

Preventive measures must take into account that there is a high risk of vitamin D insufficiency in the whole population during winter and that the elderly population, especially institutionalized subjects, are at an increased risk for vitamin D insufficiency or even deficiency. There are two prevention models available: increased exposure to ultraviolet light and increased oral vitamin D intake. Sunlight provides the most potent source of vitamin D, to ultraviolet light and increased oral vitamin D intake. These doses are quite difficult to obtain without routine supplementation, particularly in areas with extreme win-
ter climates and higher latitudes\textsuperscript{[104]} The United States Food and Drug Administration reported that a dose of 2000 IU daily is safe\textsuperscript{[21]} The Institute of Medicine of the National Academies has recently suggested a new tolerable upper intake level of only 4000 IU of vitamin D per day for the general adult population\textsuperscript{[103]} because of the concern about potential toxicity at higher levels of 25(OH)D\textsubscript{3}\textsuperscript{[105-106]} However, currently there is no recommended daily intake dose for vitamin D For a practical approach, maintenance therapy can be continued by routine sunlight exposure or by administering vitamin D supplements, 800 to 2000 IU vitamin D3 daily or 50000 IU of either D2 or D3 every 2 wk\textsuperscript{[102,107]}

**RECOMMENDATIONS**

It is still unproven whether supplementation with vitamin D reduces the cardiovascular risks. Autier \textit{et al}\textsuperscript{[108]} analyzed 18 independent randomized controlled trials of more than 57000 participants with mean follow-up of 5.7 years. Although there was considerable variability in the dose of vitamin D administered (from 300 to 2000 IU daily), the summary relative risk for all-cause mortality was reduced by 7% with vitamin D therapy\textsuperscript{[109]} Wang \textit{et al}\textsuperscript{[109]} performed a meta-analysis of 8 randomized trials, showing a slight, but statistically nonsignificant, 10% reduction in CV disease risk with vitamin D supplementation at moderate to high doses (approximately 1000 IU daily). Another meta-analysis evaluated the relationship between vitamin D levels and cardiovascular risk and reported that vitamin D was associated with nonsignificant effects on the patients’ death, myocardial infarction and stroke rates\textsuperscript{[109]} However, this study did not focus on the effect of vitamin D supplementation in the reduction of cardiovascular risks. At the present stage, we still feel confident that the benefits of vitamin D will likely outweigh the risks. A large double-blind randomized placebo-controlled trial (Vitamin D and Omega-3 Trial, VITAL) sponsored by the National Institutes of Health and run by Harvard Medical School and the Brigham and Women’s Hospital is underway\textsuperscript{[109]} This study should help to determine whether increasing low vitamin D levels will reduce the risk of CV events, depression, and death. O’Keefe \textit{et al}\textsuperscript{[111]} have claimed that several large scale trials have just started but the results of these trials will not be available for another 3-5 years or more; in the meantime, they recommend a daily intake of 1500 to 2000 IU of vitamin D3 for most American adults.

**CONCLUSION**

On the basis of this review, hypovitaminosis D has been observed worldwide, and many studies have demonstrated a strong association between vitamin D status and cardiovascular disease risk factors, including hypertension, diabetes, metabolic syndrome and inflammation. In the meantime, health professionals should be aware of the potential negative implications of vitamin D insufficiency and make recommendations for their patients to improve their vitamin D status. We suggest that to maintain health in younger and older adults and prevent hypertension, chronic heart diseases, and cardiovascular events, an increase in the current recommended intake of vitamin D is warranted. However, definitive randomized controlled trials are still needed to determine whether vitamin D therapy is beneficial to preventing cardiovascular disease. Given the low cost, safety, and demonstrated benefits of higher 25(OH)D concentration, vitamin D supplementation should become a public health priority to combat these common and costly chronic cardiovascular diseases.

**REFERENCES**

1. Holick MF. Vitamin D and sunlight: strategies for cancer prevention and other health benefits. \textit{Clin J Am Soc Nephrol} 2008; 3: 1548-1554 [PMID: 18580652 DOI: 10.2215/CJN.01350308]
2. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). \textit{Cancer Causes Control} 2000; 11: 847-852 [PMID: 11075874]
3. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. \textit{Am J Clin Nutr} 2006; 84: 18-28 [PMID: 16825677]
4. Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, Hollis WB, Giovannucci EL. Plasma vitamin D metabolites and risk of colorectal cancer in women. \textit{Cancer Epidemiol Biomarkers Prev} 2004; 13: 1502-1508 [PMID: 15342452]
5. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, Holick MF. The role of vitamin D in cancer prevention. \textit{Am J Public Health} 2006; 96: 252-261 [PMID: 16580575 DOI: 10.2105/AJPH.2004.045260]
6. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, Willett WC. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. \textit{J Natl Cancer Inst} 2006; 98: 451-459 [PMID: 16595781 DOI: 10.1093/jnci/dji101]
7. Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, Newmark HL, Giovannucci E, Wei M, Holick MF. Vitamin D and prevention of colorectal cancer. \textit{J Steroid Biochem Mol Biol} 2005; 97: 179-194 [PMID: 16236494 DOI: 10.1016/j.jsbmb.2005.06.018]
8. Holick MF. High prevalence of vitamin D inadequacy and implications for health. \textit{Mayo Clin Proc} 2006; 81: 353-373 [PMID: 16529140 DOI: 10.4065/81.3.353]
9. Holick MF. Resurrection of vitamin D deficiency and rickets. \textit{J Clin Invest} 2006; 116: 2002-2072 [PMID: 16886050 DOI: 10.1172/JCI29449]
10. Holick MF. Vitamin D deficiency. \textit{N Engl J Med} 2007; 357: 266-281 [PMID: 17634462 DOI: 10.1056/NEJMoa070553]
11. Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. \textit{Mayo Clin Proc} 2003; 78: 1463-1470 [PMID: 14661675 DOI: 10.4065/78.12.1463]
12. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS. Hypovitaminosis D in medical inpatients. \textit{N Engl J Med} 1998; 338: 777-783 [PMID: 9504937 DOI: 10.1056/NEJM199810193381201]
13. Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF, Heaney RP, Holick MF, Hollis BW, Lamberg-Allardt C, McGrath J, Norman AW, Scragg R, Whiting SJ, Willett WC, Zittermann A. The urgent need to recommend an intake of vitamin D that is effective. \textit{Am J Clin Nutr} 2007;
mote vitamin D3 synthesis in human skin. 

 latitude on the cutaneous synthesis of vitamin D3: exposure sorption varies within the reference range for serum 25-hydroxyvitamin D. 

 Heaney RP, Siris ES, Binkley N, Khan AK, Katzer JT, Petruschke RA, Chen E, de Papp AE. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005; 90: 3215-3224 [PMID: 15799594 DOI: 10.1210/jc.2004-2364] 

 Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003; 22: 142-146 [PMID: 12672710 DOI: 10.1080/073157203.2003.10791927] 

 Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988; 67: 373-378 [PMID: 2839357 DOI: 10.1210/jcem-67-2-373]
Lind L, Lithell H, Skarfors E, Wide L, Ljunghall S. Reduction of blood pressure by treatment with alfacalcidol. A double-blind, placebo-controlled study in subjects with impaired glucose tolerance. *Acta Med Scand* 1988; 222: 211-217.

Lind L, Wengle B, Wide L, Störensen OH, Ljunghall S. Hypertension in primary hyperparathyroidism—reduction of blood pressure by long-term treatment with vitamin D (al-facalcidol). A double-blind, placebo-controlled study. *Am J Hypertens* 1988; 1: 397-402.[PMID: 3063290 DOI: 10.1093/ahj/1.4.397]

Longenecker CT, Hileman CO, Carman TL, Ross AC, Seyd- dafshan S, Brown TT, Labbate DE, Storer N, Pangrichia V, McComsey GA. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. *Anticlot Ther* 2012; 17: 613-621.[PMID: 22293363 DOI: 10.3851/IMP1983]

Salehpour A, Shidfar F, Hosseinpanah F, Vafa M, Razaghi M, Hoshiaarrad A, Gohari M. Vitamin D3 and the risk of CVD in overweight and obese women: a randomised controlled trial. *Br J Nutr* 2012; 108: 1866-1873.[PMID: 22317756 DOI: 10.1017/S0007114512000098]

Shedeed SA. Vitamin D supplementation in infants with chronic congestive heart failure. *Pediatr Cardiol* 2012; 33: 713-719.[PMID: 22349668 DOI: 10.1007/s00246-012-0199-6]

Witham MD, Dove FJ, Sugden JA, Doney AS, Struthers AD. The effect of vitamin D replacement on markers of vascular health in stroke patients—a randomised controlled trial. *Nutr Metab Cardiovasc Dis* 2012; 22: 864-870.[PMID: 21194910 DOI: 10.1016/j.numecd.2010.11.001]

Zittermann A, Frisch S, Berthold HK, Göttig C, Kuhn J, Kleesiek K, Stehle P, Koerter H, Koerfer R. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. *Am J Clin Nutr* 2009; 89: 1321-1327.[PMID: 19321573 DOI: 10.3945/ajcn.2008.27004]

Gepner AD, Ramamurthy R, Krueger DC, Korcarz CE, Bin- kley N, Stein JH. A prospective randomized controlled trial of the effects of vitamin D supplementation on cardiovascular disease risk. *PLoS One* 2012; 7: e36617.[PMID: 22586483 DOI: 10.1371/journal.pone.0036617]

Jorde R, Sneve M, Torjesen P, Figschau Y. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. *Int J Med Sci* 2010; 267: 462-472.[PMID: 20141565 DOI: 10.1186/1753-1075-2009-208118]

Markmann P, Agerskov H, Thineshkar S, Bladbjerg EM, Sidelmann JJ, Jespersen J, Nybo M, Rasmussen LM, Hansen D, Scholze A. Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. *Nephrol Dial Transplant* 2012; 27: 3523-3531.[PMID: 22822092 DOI: 10.1093/ndt/gfs138]

Muldowney S, Lucey AJ, Hill TR, Seaman KM, Taylor N, Wallace JM, Horigan G, Barnes MS, Bonham MP, Duffy EM, Strain JF, Cashman KD, Kielty M. Mineralocorticoid activity of vitamin D. *Acta Med Scand* 2006; 211: 215-217.[PMID: 16000924]

Wu-Wong JR, Nakane M, Ma J, Ruan X, Kroeger PE. Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. *J Clin Invest* 1999; 83: 754-759.[PMID: 16000924]

Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. *Kidney Int* 1999; 56: 383-392.[PMID: 10432376 DOI: 10.1046/j.1523-1755.1999.00755.x]
cular disease and vitamin D insufficiency into perspective. Br J Nutr 2005; 94: 483-492 [PMID: 16197590 DOI: 10.1079/ BJN20051544]

93 Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238 [PMID: 12122115]

94 Gupta SS, Thadhani RI, Mak RH. The effect of vitamin D status on risk factors for cardiovascular disease. Nat Rev Nephrol 2013; 9: 337-347 [PMID: 23696564 DOI: 10.1038/nrneph.2013.74]

95 McCarron DA, Morris CD, Bukoski R. The calcium paradox of essential hypertension. Am J Med 1987; 82: 27-33 [PMID: 5434831 DOI: 10.1016/0002-9343(87)90268-3]

96 MacGregor GA, Cappuccio FP. The kidney and essential hypertension: a link to osteoporosis? J Hypertens 1993; 11: 781-785 [PMID: 8228200 DOI: 10.1007/BF00487299-19930800-00003]

97 Strauzzullo P. The renal calcium leak in primary hypertension: pathophysiological aspects and clinical implications. Nutr Metab Cardiovasc Dis 1991; 1: 95-103

98 Scragg R, Holdaway I, Jackson R, Lim T. Plasma 25-hydroxyvitamin D3 and its relation to physical activity and other heart disease risk factors in the general population. Ann Epidemiol 1992; 2: 697-703 [PMID: 1342521 DOI: 10.1016/1047-2797(92)90014-H]

99 Dustan HP. Obesity and hypertension in blacks. Cardiovasc Drugs Ther 1990; 4 Suppl 2: 395-402 [PMID: 2271401 DOI: 10.1087/BFD0256185]

100 Harris SS, Dawson-Hughes B. Seasonal changes in plasma 25-hydroxyvitamin D concentrations of young American black and white women. Am J Clin Nutr 1998; 67: 1232-1236 [PMID: 9625098]

101 Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 2003; 89: 552-572 [PMID: 12720576 DOI: 10.1079/BJN2003837]

102 Van Lente F. Markers of inflammation as predictors in cardiovascular disease. Clin Chim Acta 2000; 293: 31-52 [PMID: 10699421 DOI: 10.1016/S0002-9898(99)00236-3]

103 Mendall MA, Patel P, Asante M, Ballam L, Morris J, Strachan DP, Camm AJ, Northfield TC. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 1997; 81: 275-277 [PMID: 9391290]

104 Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1999; 19: 54-58 [PMID: 988866 DOI: 10.1161/01.ATV.19.1.54]

105 Polverini PJ, Cotran PS, Gimbrone MA, Unanue ER. Activated macrophages induce vascular proliferation. Nature 1977; 269: 804-806 [PMID: 927505 DOI: 10.1038/269804a0]

106 Signore A, Annovazzi A, Corsetti F, Capriotti G, Chianelli M, De Winter F, Scarpinato F. Biological imaging for the diagnosis of inflammatory conditions. BioDrugs 2002; 16: 241-259 [PMID: 12196038 DOI: 10.2165/00063030-200207040-00002]

107 Sullivan GW, Sarembock IJ, Linden J. The role of inflammation in vascular diseases. J Leukoc Biol 2000; 67: 591-602 [PMID: 10810997]

108 Tamagaki AN, Buda AJ, Wilkins RG, Barron MK, Jeffords PR, Vo K, Jordan MO, Kusnick BA, Lefer DJ. Levels of expression of P-selectin, E-selectin, and intercellular adhesion molecule-1 in coronary athrectomy specimens from patients with stable and unstable angina pectoris. Am J Cardiol 1997; 79: 742-747 [PMID: 9075552 DOI: 10.1016/S0002-9149(96)00861-2]

109 Ueyama K, Demer LL, Castle SC, Jillian D, Berliner JA, Gately MK, Warrier RR, Pham N, Fogelman AM, Modlin RL. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996; 97: 2130-2138 [PMID: 8621803 DOI: 10.1172/JCI118650]

110 Zittermann A, Schleithoff SS, Koerfer R. Putting cardiovas-
Ku YC et al. Vitamin D and cardiovascular disease

106 Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Report of the Institute of Medicine of the National Academies, Washington, DC: The National Academies Press, 2011

107 Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77: 204-210 [PMID: 12499343]

108 Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167: 1730-1737 [PMID: 17846391 DOI: 10.1001/archinte.167.16.1730]

109 Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, Almandoz JP, Liu H, Lane MA, Mullan RJ, Hazem A, Erwin PJ, Hensrud DD, Murad MH, Montori VM. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96: 1931-1942 [PMID: 21677037 DOI: 10.1210/jc.2011-0398]

110 Vitamin D and Omega-3 Trial (VITAL). ClinicalTrials.gov ID: NCT01169259. Cited 2013-08-21. Available from: URL: http://clinicaltrials.gov/show/NCT01169259

111 O’Keefe JH, Patil HR, Lavie CJ. Can vitamin D deficiency break your heart? Mayo Clin Proc 2012; 87: 412-413; author reply 413 [PMID: 22469354 DOI: 10.1016/j.mayocp.2011.12.013]

P- Reviewers Georgescu A, Su H  S- Editor Song XX  L- Editor A  E- Editor Lu Y
